Loading
Latest filing published 20 Aug 2025 for ALX Oncology Holdings INC, €50k. Read the official filing
No signal scores available.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This profile gathers the share dealings of Harish Shantharam across 2 companies, led by CymaBay Therapeutics, Inc. and ALX Oncology Holdings Inc. The record holds 3 filings, for trades running from 24 January 2024 to 18 August 2025.
Every open-market trade on record is a purchase: 1 purchase worth €50k, and no sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 1 share grant. Since January 2025: 1 purchase and no sales on the market.
The newest entry dates from 20 August 2025: an open-market purchase of €50k, in ALX Oncology Holdings Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations